Development Of Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry (REPTT): A Study Proposal Of The Spanish Society Of Hematology And Hemotherapy (SEHH) Whit The Portuguese Society Of Hematology (SPH)

Status: Recruiting
Location: See all (7) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

REPTT is an observational, prospective, multi-country, multicentre and non-interventional registry in which at least 300 patients with Thrombotic thrombocytopenic purpura (TTP) in Spain and Portugal will be evaluated. The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 99
View:

• Patients with diagnosis of TTP according to International Consensus criteria from centres in Spain and Portugal.

• Patients that voluntarily sign the informed consent. For subjects unable to provide informed consent, a fully recognized medical authority may be used according to local laws.

• Patients between 0 to 99 years old at the time of diagnosis.

⁃ Note: Decision was taken to treat the patient with an specific treatment prior and independently of patient inclusion in this non interventional study.

Locations
Other Locations
Spain
Hospital Clínic Barcelona
RECRUITING
Barcelona
Hospital Universitario de Guadalajara
RECRUITING
Guadalajara
Hospital Universitario Bellvitge
RECRUITING
L'hospitalet De Llobregat
Hospital Universitario La Paz
RECRUITING
Madrid
Hospital Virgen de la Arrixaca
RECRUITING
Murcia
Hospital Universitario Virgen del Rocío
RECRUITING
Seville
Hospital Clínico Universitario de Valencia
RECRUITING
Valencia
Contact Information
Primary
Contact person Designated by the Sponsor
investigacion@mfar.net
+34934344412
Time Frame
Start Date: 2024-03-22
Estimated Completion Date: 2026-12
Participants
Target number of participants: 300
Treatments
Thrombotic thrombocytopenic purpura patients
Including all patients enrolled in the study
Related Therapeutic Areas
Sponsors
Leads: Fundación Española de Hematología y Hemoterapía

This content was sourced from clinicaltrials.gov

Similar Clinical Trials